Loading provider…
Loading provider…
Hepatology Physician in New York, NY
NPI: 1457448540Primary Practice Location
NYU LANGONE HOSPITALS
150 55th St, Brooklyn, NY
Primary Employer
NYU Faculty Group Practice
nyulangone.org
HQ Phone
Get MD Samuel's Phone Numberphone_androidMobile
Get MD Samuel's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
NY State Medical License
Montefiore Medical Center
fellowship • Gastroenterology
1990 - 1993
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 39 | 59 |
| 2 | 99231Subsequent hospital inpatient care, typically 15 minutes per day | 35 | 59 |
| 3 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 32 | 60 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 28 | 33 |
| 5 | 99221Initial hospital inpatient care, typically 30 minutes per day | 26 | 27 |
Authors: Hearns Charles, Hersh Chandarana
Journal: World J Gastroenterol
Authors: Nguyen, Julie, Shashank, Mandira, Birnbaum, Jessie A, Omarufilo, Fatima, Emeasoba, Emmanuel U, Boakye, Kwabena, Guttman, Daniel, Parulekar, Mugdha, Fisher, Molly, Sigal, Samuel H
Journal: Lancet Reg Health Am
Publication Date: 2024-05-21
Lead Sponsor: Intercept Pharmaceuticals
Intervention / Treatment: DRUG: Placebo, DRUG: Obeticholic acid (10 mg), DRUG: Obeticholic acid (10 mg to 25 mg)
Lead Sponsor: Intercept Pharmaceuticals
Intervention / Treatment: DRUG: Placebo, DRUG: Obeticholic Acid
Lead Sponsor: Inovio Pharmaceuticals
Intervention / Treatment: BIOLOGICAL: INO-9112, DRUG: Nucleos(t)ide Analogue Treatment, BIOLOGICAL: INO-1800